Journal
ONCOLOGY REPORTS
Volume 37, Issue 5, Pages 2883-2890Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2017.5507
Keywords
miR-429; TRAF6; hepatocellular carcinoma
Categories
Funding
- National Natural Science Foundations of China [81372632, 81402579]
- Special Funds of Post Doctoral Innovation Projects of Shandong Province of China [201303063]
- Application of Post Doctoral funds of Qingdao city, Shandong Province of China [20130118]
Ask authors/readers for more resources
Increasing evidence indicates that miR-429 is involved in tumor suppression in various human cancers. However, its role in hepatocellular carcinoma (HCC) remains unclear. In the present study, we found that miR-429 was significantly downregulated in HCC tissue samples and cell lines. Upregulation of miR-429 markedly suppressed proliferation and migration of HCC cells. Moreover, we identified TRAF6 as a direct target of miR-429. Downregulation of TRAF6 partially attenuated the oncogenic effect of anti-miR-429 on HCC cells. Ectopic expression of miR-429 in HCC cells inhibited TCF-4 activity as well as nuclear accumulation of P65 and expression of the NF-kappa B targets c-Myc and phosphorylation of TAK1. In a nude xenograft model, miR-429 upregulation significantly decreased HCC growth. In conclusion, by targeting TRAF6, miR-429 is downregulated in HCC and inhibits HCC cell proliferation and motility. Our data suggest that miR-429 may serve as a potential anticancer target for the treatment of HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available